An orally bioavailable, non-peptide GH secretagogue that mimics ghrelin to robustly stimulate pituitary GH release without affecting cortisol significantly.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →MK-677, also known by the nonproprietary name ibutamoren and sometimes referred to as ibutamoren mesylate, occupies an unusual position in the growth hormone secretagogue research space: it is not a peptide. Despite being frequently discussed alongside peptides like GHRP-2, GHRP-6, and ipamorelin, MK-677 is a small organic molecule — a spiropiperidine derivative — developed by Merck & Co. through a discovery program specifically aimed at finding orally bioavailable compounds that could mimic the GH-releasing effects of ghrelin and related peptide secretagogues.
The development rationale was compelling from a pharmaceutical engineering perspective. Peptide GH secretagogues require injection because they are degraded in the gastrointestinal tract and poorly absorbed intact. A small molecule that could activate the same receptor orally would have obvious practical advantages for any chronic therapeutic application. Merck’s program succeeded in producing MK-677, which is orally bioavailable, has a long plasma half-life (approximately 24 hours in humans), and produces robust, sustained GH elevation following a single daily oral dose.
MK-677 works by mimicking ghrelin, the endogenous “hunger hormone” produced primarily in the stomach. Ghrelin serves multiple physiological functions including stimulating appetite, regulating energy balance, and signaling the pituitary to release growth hormone through the growth hormone secretagogue receptor 1a (GHS-R1a). MK-677 binds to GHS-R1a with high affinity and activates the GH-releasing cascade — but unlike peptide ghrelin analogs, it does so with oral bioavailability and a pharmacokinetic profile that sustains GH elevation over 24 hours rather than the brief pulses produced by injectable secretagogues.
Merck conducted MK-677 through extensive clinical investigation across multiple indications including growth hormone deficiency, muscle wasting in the elderly (cachexia), osteoporosis, and metabolic syndrome through the late 1990s and 2000s. The compound was ultimately not advanced to regulatory approval by Merck, despite substantial positive efficacy data, primarily due to the identification of concerns about fluid retention and potential impacts on insulin resistance at doses that produced meaningful anabolic effects. However, the extensive published clinical research generated during Merck’s program — including multiple randomized controlled trials in elderly populations — provides an unusually complete evidence base for a compound that never achieved regulatory approval.
MK-677’s 24-hour GH elevation profile distinguishes it mechanistically and pharmacodynamically from both exogenous hGH and from injectable GHRH analogs or GH secretagogue peptides, all of which have shorter windows of activity. This sustained elevation has both advantages (consistent anabolic and metabolic signaling) and disadvantages (persistent appetite stimulation, sustained insulin antagonism). Understanding these tradeoffs is central to interpreting the MK-677 research literature. Browse related GH-axis compounds in our peptide database.
MK-677’s mechanism of action centers on its agonist activity at the growth hormone secretagogue receptor type 1a (GHS-R1a), also called the ghrelin receptor. GHS-R1a is a G protein-coupled receptor expressed in the anterior pituitary, the hypothalamus, and multiple peripheral tissues including the stomach, heart, and adipose tissue. The endogenous ligand, ghrelin, is an acylated 28 amino acid peptide produced primarily by gastric X/A-like cells that signals nutritional status, stimulates appetite, and triggers GH release from pituitary somatotrophs. When ghrelin binds GHS-R1a, it activates phospholipase C through Gq coupling, generating IP3 and diacylglycerol, which collectively raise intracellular calcium and activate protein kinase C — ultimately stimulating GH exocytosis. MK-677 activates GHS-R1a through this same intracellular pathway with high potency and full agonist efficacy. Its small molecule structure, however, gives it pharmacokinetic properties that ghrelin itself lacks entirely — oral bioavailability approaching 60-70% and a half-life of approximately 24 hours versus ghrelin’s circulating half-life of minutes. This pharmacokinetic advantage is the entire strategic rationale for MK-677’s development over peptide ghrelin analogs.
The chronic GH elevation produced by once-daily MK-677 dosing reliably elevates IGF-1 levels, which are the primary downstream mediators of MK-677’s effects on lean mass, bone density, and cellular metabolism. IGF-1, produced mainly in the liver in response to GH signaling, acts through the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase whose downstream signaling through the PI3K/Akt/mTOR pathway drives protein synthesis, inhibits protein breakdown, promotes cell survival, and stimulates satellite cell proliferation in skeletal muscle. In bone, IGF-1 stimulates osteoblast activity and bone matrix deposition. In aged tissues where GH/IGF-1 axis activity has declined, MK-677-driven IGF-1 restoration partially reverses the catabolic and degenerative processes associated with somatopause (age-related GH decline). The sustained nature of MK-677’s IGF-1 elevation — as opposed to the intermittent pulsatile elevation from injectable secretagogues — means that IGF-1 receptor signaling in target tissues is activated more continuously, which may be important for the magnitude of lean mass and bone density responses seen in long-duration trials.
Activating GHS-R1a does more than just release GH — ghrelin is the primary endogenous hunger signal, and MK-677’s agonism at the ghrelin receptor inevitably engages appetite-stimulating pathways alongside its GH-releasing activity. GHS-R1a activation in the hypothalamus (particularly the arcuate nucleus and lateral hypothalamus) stimulates neuropeptide Y and agouti-related protein (NPY/AgRP) neurons, which are orexigenic (appetite-promoting). Research participants taking MK-677 consistently report increased appetite, and food intake measurements in research studies have documented significant increases in caloric consumption compared to placebo. This appetite effect has a nuanced relationship with the lean mass preservation and GH-related metabolic effects — in the elderly cachectic populations studied by Merck, increased appetite was a desired effect contributing to nutritional status improvement. In the context of body composition research in healthy adults, the appetite stimulation can partially offset the body composition benefits by facilitating increased caloric intake that replenishes fat stores. Understanding that MK-677 inherently stimulates both GH release and appetite — because both are functions of the GHS-R1a — is essential for designing research protocols and interpreting body composition outcomes.
The most robust clinical evidence for MK-677’s efficacy comes from studies in elderly populations where age-related loss of lean mass (sarcopenia) and GH/IGF-1 decline represent meaningful research targets. A landmark 12-month randomized, double-blind, placebo-controlled trial by Nass and colleagues published in the Annals of Internal Medicine enrolled healthy elderly men and women (65+) to MK-677 25 mg daily or placebo. Results showed significant increases in lean body mass (measured by DEXA) in the treated group compared to placebo — approximately 1.5-2 kg of added lean mass over 12 months. Fat mass did not increase significantly in the treated group despite the appetite stimulation, suggesting that the GH-driven increase in lipolysis and metabolic rate offset the increased caloric intake. A shorter-duration study specifically examining the ability of MK-677 to prevent catabolic protein loss during caloric restriction demonstrated that 7 days of MK-677 administration completely blocked the negative nitrogen balance (protein catabolism) induced by a severely caloric-restricted diet in healthy young volunteers, establishing the compound’s capacity to preserve lean mass under nutritional stress conditions that are extremely relevant to clinical applications like surgical recovery and illness-related muscle wasting.
Merck’s clinical program included extended studies examining MK-677’s effects on bone density in populations at risk for osteoporosis. A two-year randomized trial in elderly women with hip fractures (a population with severe sarcopenia and bone fragility risk) found that MK-677 administration significantly increased bone formation biomarkers — specifically osteocalcin and bone-specific alkaline phosphatase — over the study period. Importantly, bone resorption markers also increased initially, reflecting the coupled nature of bone remodeling where formation and resorption increase together during anabolic stimulation, but the net balance shifted toward bone formation over longer follow-up. DEXA-measured bone mineral density at the hip and lumbar spine showed significant improvements compared to placebo over 24 months, effect sizes that are clinically meaningful given the fracture risk implications of BMD improvements in this population. These findings positioned MK-677 as a potentially useful tool for osteoporosis research and treatment, a rationale that remains scientifically coherent even though the compound was not developed to an approved therapy in this indication.
An intriguing and sometimes overlooked area of MK-677 research is its effects on sleep architecture. GHS-R1a activation by ghrelin is known to influence sleep, and MK-677’s sustained GHS-R1a activity over 24 hours has been shown to alter sleep EEG characteristics. Frieboes and colleagues conducted a study in healthy young and elderly males examining polysomnographic outcomes after MK-677 versus placebo administration. Results showed that MK-677 significantly increased the duration of stage 4 (delta/slow-wave) sleep and REM sleep in both age groups, with the REM sleep increase being particularly consistent. The proposed mechanism involves GHS-R1a activation in brainstem regions that regulate sleep stage cycling, particularly for REM sleep generation. The slow-wave sleep enhancement may be partly mediated by the GH pulses triggered by MK-677, since GH secretion and deep NREM sleep are tightly coupled in normal physiology. These sleep improvements are not simply sedation — they represent enhancement of specific sleep stages associated with cognitive consolidation, tissue repair, and hormonal restoration that occur during deep sleep. The sleep research adds a dimension to MK-677’s effects that goes beyond simple lean mass and GH secretion outcomes.
Merck’s development program for MK-677 included extended safety monitoring across multiple clinical trials, generating a safety dataset that extends to 24 months in some cohorts — longer than most research peptide safety data. The primary safety concerns identified were consistent with the known pharmacology of GH excess: water retention and transient edema, increased fasting glucose and insulin resistance, and a small but measurable increase in systolic blood pressure in some cohorts. The metabolic adverse effects — particularly the insulin resistance — emerged as a key limitation in GH-deficient adults and in older participants where baseline insulin sensitivity was already reduced. In the elderly sarcopenia trials, the positive lean mass and bone density outcomes had to be weighed against these metabolic effects, and the balance was considered potentially acceptable for high-need populations but not for general use in healthy elderly adults without significant muscle loss. No serious cardiovascular events, malignancies, or mortality differences were identified in the trial population, and the compound was generally well-tolerated at the doses studied.
Studies in adults with adult-onset growth hormone deficiency (AGHD) examined whether MK-677 could serve as an oral alternative to injectable hGH for IGF-1 restoration. In these patients, who have structural or functional pituitary deficiency and cannot secrete adequate GH endogenously, MK-677 can stimulate residual pituitary GH secretion if some somatotroph function remains. Studies found that MK-677 increased IGF-1 to near-normal or normal levels in a significant proportion of GH-deficient patients, with improvement in body composition, bone density, and quality of life measures. However, patients with complete pituitary failure obviously would not respond, and the variability in pituitary responsiveness across AGHD patients makes MK-677 unreliable as a universal oral GH replacement. This research established an important mechanistic boundary: MK-677 requires a functional pituitary GHS-R1a system to work, distinguishing it from exogenous hGH which delivers GH directly regardless of pituitary status.
The Merck clinical program investigated MK-677 doses ranging from 10 mg to 50 mg per day administered orally. The dose showing the most favorable balance of GH/IGF-1 elevation versus side effect burden across multiple studies was 25 mg once daily, which became the most commonly used dose in the later-stage trials. Lower doses (10-15 mg) produced more modest GH and IGF-1 elevation but with fewer metabolic side effects and less appetite stimulation — a potentially more practical profile for elderly or metabolically vulnerable populations. The 50 mg dose produced strong GH/IGF-1 responses but was associated with more frequent fluid retention and glucose elevation. Administration timing in the published studies was typically once daily, often in the evening given ghrelin’s natural peak secretion in the evening and the sleep architecture benefits observed with nighttime GHS-R1a activation. Our peptide reference calculators include tools for working with GH secretagogue research parameters.
MK-677 has been studied in protocols ranging from 7 days (the catabolism prevention study) to 24 months (the bone density studies). The lean mass research suggests that effects on body composition become more pronounced with longer treatment duration — 12-month outcomes were more robust than 3-month outcomes in the elderly trials. For bone density research, the 12-24 month timeframe appears necessary to capture meaningful BMD changes given the slow turnover rate of bone. Short-term protocols (4-8 weeks) are most informative for acute pharmacodynamic measurements (GH pulse profiles, IGF-1 dose-response, nitrogen balance) rather than body composition or structural endpoints. Long-term use beyond 24 months has not been systematically studied in controlled trials.
One of MK-677’s defining features is oral administration, which eliminates reconstitution requirements, injection technique, and the sterility concerns associated with parenteral peptide use. It is typically supplied as a capsule or tablet and taken once daily. Food intake timing relative to MK-677 administration has been examined in pharmacokinetic studies — food modestly slows absorption rate without significantly affecting total bioavailability (AUC), so it can be taken with or without food. The appetite-stimulating effects are most pronounced within a few hours after dosing, which is an important practical consideration for timing in research protocols where food intake is being controlled or measured.
MK-677 has never received regulatory approval in any jurisdiction for any indication despite the substantial clinical trial program. It is not a pharmaceutical drug, not a scheduled controlled substance in most countries, and not approved as a dietary supplement by the FDA (which has specifically issued guidance that MK-677 is not a legal dietary supplement ingredient). It exists in a legal gray area in most jurisdictions — not explicitly prohibited in many places, but also not approved for human consumption. The research use in academic and pharmaceutical contexts proceeds under appropriate regulatory oversight. Anyone considering MK-677 should verify current legal status in their jurisdiction. The AI peptide coach can provide general informational context on regulatory considerations for MK-677 research.
The most consistently documented adverse effects of MK-677 across the clinical trial literature are those expected from sustained GH elevation: fluid retention, peripheral edema, joint pain (arthralgia), carpal tunnel syndrome, and increased fasting glucose or insulin resistance. Fluid retention occurred in a substantial minority of trial participants, typically manifesting as dependent edema and transient weight gain that was clearly distinguishable from lean mass gain on body composition analysis. Arthralgia and carpal tunnel symptoms are characteristic of GH excess in general and resolved in most participants with dose reduction. The insulin resistance finding is mechanistically expected — GH is a counter-regulatory hormone to insulin, and sustained GH elevation produces a predictable degree of glucose impairment. In metabolically healthy younger adults, this may remain within the normal range, but in insulin-resistant or pre-diabetic individuals, MK-677 can meaningfully worsen glucose parameters.
The appetite stimulation from GHS-R1a agonism is not a trivial or incidental side effect — it is a direct, mechanistically expected consequence of activating the ghrelin receptor. Clinical trial participants consistently reported increased hunger, and food intake measurements confirmed increased caloric consumption. In elderly cachectic patients, this is a desired therapeutic effect. In other populations, it represents a significant practical challenge for body composition management. The increased appetite effect can substantially complicate the interpretation of body composition outcomes in research studies — observed fat mass changes reflect the net of GH-driven lipolysis, IGF-1-driven lean mass accretion, and appetite-driven increased caloric intake, making it difficult to attribute changes to any single mechanism. Research protocols that measure food intake alongside body composition provide more interpretable data than those measuring body composition alone.
The two-year safety data from Merck’s clinical program identified no statistically significant increase in cancer incidence in MK-677-treated participants compared to placebo. However, as with tesamorelin and other compounds that elevate IGF-1, the theoretical concern about cancer risk with sustained IGF-1 elevation warrants ongoing vigilance. IGF-1 is a pro-survival and mitogenic signal that could theoretically support growth of occult malignancies, and epidemiological data associating chronically elevated IGF-1 levels with cancer risk is established in the observational literature. The 24-month trial duration is insufficient to definitively characterize long-term cancer risk, and the absence of statistical significance in the trial populations does not mean the risk is zero — the trials were not powered to detect modest risk increases. For research involving long-term MK-677 administration, cancer risk considerations are part of the ethical framework that must be addressed in protocol design. Individuals with personal or family histories of hormone-sensitive cancers (breast, prostate, colorectal) are the population where this concern is most practically relevant.
No, and this distinction matters for understanding its mechanism, pharmacokinetics, and regulatory status. MK-677 is a small organic molecule — specifically a spiropiperidine derivative — with a molecular weight around 624 Da. Peptides are chains of amino acids connected by peptide bonds; MK-677 contains no peptide bonds. It was designed to mimic the GH-releasing effects of peptide ghrelin analogs but with oral bioavailability that peptides lack. The reason it is discussed alongside peptides in research circles is functional — it activates the same GHS-R1a receptor as peptide ghrelin analogs — but its chemistry, pharmacokinetics, and regulatory classification are fundamentally different from peptides.
Both MK-677 and peptide GH secretagogues (GHRP-2, GHRP-6, ipamorelin, hexarelin) activate GHS-R1a and stimulate GH release. The key differences are: oral bioavailability (MK-677 yes, peptide secretagogues no), duration of action (MK-677 ~24 hours, peptide secretagogues 2-4 hours requiring multiple daily injections), and the temporal pattern of GH elevation (MK-677 produces tonic sustained elevation, peptide secretagogues produce acute spikes). Whether sustained versus pulsatile GH elevation is preferable for specific research endpoints is an unresolved question — physiological GH secretion is pulsatile, but the anabolic effects on lean mass appear to require sufficient sustained IGF-1 elevation that the longer MK-677 effect window may actually be advantageous for some outcomes.
This is an important mechanistic distinction from exogenous hGH. Because MK-677 stimulates endogenous GH release through the natural GHS-R1a pathway rather than delivering GH exogenously, it does not suppress the GH axis in the way that exogenous hGH does. When MK-677 is discontinued, the pituitary’s capacity to secrete GH is preserved and the GH axis returns to its prior baseline. There is no equivalent to the pituitary suppression seen with long-term exogenous GH administration. This is a practical and mechanistic advantage that makes MK-677 research protocols more straightforward from a post-discontinuation perspective.
This is a complex business and scientific question. The core issue was likely the difficulty of finding an indication with a favorable enough benefit/risk ratio to justify regulatory approval. The lean mass benefits in elderly sarcopenia were real but modest in absolute terms, and they were accompanied by fluid retention and glucose impairment that complicates the benefit/risk calculus in a geriatric population already at metabolic risk. The GH deficiency indication was feasible but the market was already served by injectable hGH. The bone density data was promising but required very long study durations to show meaningful effects. The compound ultimately did not find a “Goldilocks” indication where the benefits were clearly compelling and the risks acceptable to regulators. This is a common fate in pharmaceutical development and says nothing about whether the compound might find research or clinical utility in specific well-defined contexts.
Controlled polysomnographic research found that MK-677 significantly increased both REM sleep duration and stage 4 (slow-wave/delta) sleep duration. These are the sleep stages most associated with cognitive memory consolidation (REM) and physical recovery/GH secretion (stage 4). The mechanism involves GHS-R1a activation in brainstem structures that regulate sleep staging, particularly the regulation of REM sleep transitions, combined with the known coupling between GH secretory pulses and slow-wave sleep. Participants in sleep studies also reported improved subjective sleep quality scores. This represents a potentially clinically valuable effect distinct from the body composition and GH-axis effects, particularly for populations with age-related sleep architecture deterioration.
The glucose-impairing effect of MK-677 is dose-related and population-dependent. At lower doses (10 mg), the insulin resistance signal is more modest than at 25 or 50 mg. In healthy metabolically normal young adults, the glucose impairment at standard doses often remains within the normal range on standard clinical tests, though measurable increases in fasting insulin and HOMA-IR have been documented. In older adults with pre-existing insulin resistance, metabolic syndrome, or prediabetes, clinically meaningful glucose impairment is more likely to emerge. Monitoring fasting glucose and insulin during MK-677 research protocols is standard practice. The insulin resistance mechanism involves GH’s established counter-regulatory activity against insulin signaling at the post-receptor level in liver and muscle.
MK-677 (ibutamoren) is on the World Anti-Doping Agency (WADA) prohibited list as a GH secretagogue, falling under the prohibited category of peptide hormones, growth factors, related substances, and mimetics. It is detectable in urine samples by specific mass spectrometry testing used in athletic drug testing programs. Detection windows depend on the dose and the sensitivity of the testing method, but ibutamoren can potentially be detected for several days to weeks after last use depending on testing methodology. Athletes subject to WADA testing or national anti-doping program oversight should be aware of this prohibition and detection capability.
Our peptide database includes detailed profiles for MK-677 alongside related GH secretagogues and GHRH analogs for comparative reference. The calculators section provides tools relevant to GH-axis research parameters, and the AI peptide coach can answer general informational questions about published MK-677 research methodology and study designs.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.